<DOC>
	<DOCNO>NCT01452373</DOCNO>
	<brief_summary>The purpose Phase III trial evaluate efficacy oral administration dehydroepiandrosterone ( DHEA ) combine acolbifene ( selective estrogen receptor modulator ( SERM ) ) vasomotor symptom ( hot flush ) postmenopausal woman .</brief_summary>
	<brief_title>Dehydroepiandrosterone ( DHEA ) + Acolbifene Against Vasomotor Symptoms ( Hot Flushes ) Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>Main Postmenopausal woman ( nonhysterectomized hysterectomized ) . Women 40 75 year age . Willing participate study sign inform consent . Women many moderate severe hot flush . For nonhysterectomized woman , willing endometrial biopsy baseline end ofstudy . Main Undiagnosed abnormal genital bleeding . Hypertension equal 140/90 mm Hg . The administration investigational drug within 30 day screen visit . Endometrial hyperplasia ( simple complex hyperplasia without atypia ) , cancer endometrial histology show proliferative , secretory menstrual type characteristic histologic evaluation endometrial biopsy perform screening .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hot flush ( e )</keyword>
	<keyword>Hot flash ( e )</keyword>
	<keyword>Vasomotor symptom</keyword>
	<keyword>Dehydroepiandrosterone ( DHEA )</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Acolbifene</keyword>
	<keyword>Selective estrogen receptor modulator ( SERM )</keyword>
	<keyword>Antiestrogen</keyword>
	<keyword>Menopause</keyword>
	<keyword>Postmenopausal woman</keyword>
</DOC>